# Nasdaq's Wild Ride: Microcap Madness Unleashed! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-06-28T14:01:00.752Z Source: https://newsyai.com/edition/ebdb16de-4851-4a87-88c8-5422b3d4d0c6 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Nasdaq's Microcap Split Circus: HCWB, JBDI & CRIS Edition!**[[1]](https://finance.yahoo.com/calendar/splits/) Futures mixed (Dow flat, Nasdaq riding AI/chip rotation and Iran deal vibes), crude still sky-high. Post-holiday hangover? Markets are pure chaos with low-float squeezes, fresh reverse-split desperation, deficiency letters, and dilution daggers flying. New Nasdaq/NYSE rules are tightening the reverse-split noose on serial offenders. Yesterday’s TRNR/QNCX/PAVS limp-dicks left stains; today’s drama features fresh meat chasing $1 bids amid biotech whispers, governance ghosts, and thin-float retail frenzy. Bulls scream “listing saved, moonshot reloaded”; bears howl “next equity gangbang, sub-penny doom!” Balls-deep into three fresh volatility kings.[[2]](https://www.nortonrosefulbright.com/en-us/knowledge/publications/5b2935b6/new-nasdaq-and-nyse-rules-on-use-of-reverse-stock-splits) ### 1) HCW Biologics Inc. (HCWB): “1-for-6 Reverse-Split Stiffy vs. Inflammation Biotech Hype & Serial Split Hangover” **Why it’s loud** Brutal 1-for-6 reverse split effective June 30, 2026, to chase Nasdaq bid-price compliance—second split this year after a prior 1-for-40. Clinical-stage biotech play developing fusion immunotherapeutics for autoimmune disorders, cancer, and senescence-associated issues, with retail sniffing “post-split bounce + pipeline narrative”; bears flag repeated split vibes, thin fundamentals, and compliance theater.[[3]](https://www.biospace.com/press-releases/hcw-biologics-announces-1-for-6-reverse-stock-split-effective-on-june-30-2026) **Bull case (compliance cock rocket redux)** Thin float + split to $1+ bid + biotech oxygen = parabolic rebound to $3–10+. Ape the listing save and stiffy! **Bear case (dilution rape & split limp encore)** Nuclear ratio screams desperation, heavy overhang + past declines = sub-$0.30 bust. Short the limp before the next notice! **My take, first principles (real compliance signal vs. capital-structure cancer)** Legitimate bid-price fix provides short-term breathing room in a hot low-float environment, but the repeated splits and microcap thinness scream unsustainable structures under the new tighter Nasdaq rules. Real compliance play with real dilution risk. Scalp the spunk? **$0.50–3.00**, **$1.20C** volume stiffy—**P$0.40** fade. ### 2) JBDI Holdings Limited (JBDI): “1-for-2 Reverse-Split Hype vs. Holding Company Dreams & Nasdaq Exception Ghosts” **Why it’s loud** Stockholders approved a 1-for-2 reverse split (effective ~June 25-30, 2026) amid Nasdaq compliance push and par value tweak. Retail chase potential—bulls see “post-split lift + restructuring reset”; bears hammer execution risks, governance, and dilution ghosts.[[4]](https://www.globenewswire.com/news-release/2026/06/16/3312802/0/en/jbdi-holdings-limited-announces-reverse-stock-split.html) **Bull case (holding co cock rocket)** Sector tailwinds (Singapore-based holdings) + split mechanics + volume = $2–6+ rebound. Ape the narrative stiffy! **Bear case (delisting rape & burn limp)** Repeated compliance theater, thin results = sub-$0.40 crash. Short the limp before the next notice! **My take, first principles (real platform signal vs. listing cancer)** Genuine compliance mechanics offer narrative fuel, but microcap scale, compliance clock, and governance red flags under stricter reverse-split rules highlight classic volatility trap. Real pivot hype with real delisting risk. Scalp the spunk? **$0.40–2.50**, **$1.00C** pump—**P$0.30** fade. ### 3) Curis, Inc. (CRIS): “Flexible 1-for-5-to-25 Reverse-Split Authorization vs. CLL Study Buzz & Nasdaq Dilution Mania” **Why it’s loud** Stockholders just approved a wide reverse-split range (1-for-5 to 1-for-25) at a special meeting, paired with TakeAim CLL study updates (11 active sites, dosing guidance reaffirmed). Bulls chase momentum and trial hype; bears flag massive potential dilution, no immediate execution, and pump risks.[[5]](https://www.prnewswire.com/news-releases/curis-announces-eleven-active-clinical-sites-in-takeaim-cll-study-reaffirms-patient-dosing-guidance-and-reports-stockholder-approval-of-reverse-stock-split-302811922.html) **Bull case (squeeze & trial cock rocket)** Thin float + retail volume + oncology narrative = $1–5+ moonshot. Ape the squeeze stiffy! **Bear case (dump rape & limp encore)** Flexible ratio screams desperation + history of fades + thin results = sub-$0.20 crash. Fade the limp before the dump! **My take, first principles (real momentum signal vs. structural cancer)** Legitimate low-float fuel and clinical whispers deliver short-term fireworks, but microcap thinness, flexible nuclear ratios, and constant compliance needs underscore unsustainable structures. Real volatility play with real fade risk. Scalp the spunk? **$0.30–2.00**, **$0.80C** hype pump—**P$0.25** fade. **Tape-Side Tactics (HCWB Split Grab, JBDI Holdings Squeeze & CRIS Notice Pump – June 28 Edition)** - **HCWB**: **$0.50–3.00** compliance stiffy; **$1.20C** narrative pump, **P$0.40** dilution fade. - **JBDI**: **$0.40–2.50** holdings stiffy; **$1.00C** retail pump, **P$0.30** exception fade. - **CRIS**: **$0.30–2.00** trial stiffy; **$0.80C** study pump, **P$0.25** fade. New split rules tightening the screws amid crude cock-up and micro-madness. Balls-deep DYOR, NFA, degens duck the dilutions! **Sources** (for tracking every claim above): - Reverse splits & reactions: NasdaqTrader.com, StockTitan, BioSpace, GlobeNewswire, PR Newswire (June 2026 data).[[6]](https://nasdaqtrader.com/Trader.aspx?id=archiveheadlines&cat_id=105) - Nasdaq reverse-split rule changes & compliance: NasdaqTrader, SEC filings, Norton Rose Fulbright (2025-2026 updates).[[2]](https://www.nortonrosefulbright.com/en-us/knowledge/publications/5b2935b6/new-nasdaq-and-nyse-rules-on-use-of-reverse-stock-splits) - Broader microcap/premarket context & volatility: Benzinga, Investing.com, StockAnalysis (June 27-28, 2026). - Company specifics via recent filings and exchange alerts.